Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) EVP Eric Swayze sold 15,642 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $81.76, for a total value of $1,278,889.92. Following the sale, the executive vice president owned 32,105 shares of the company’s stock, […]

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CFO Hunter Smith sold 2,766 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $98.61, for a total value of $272,755.26. Following the transaction, the chief financial officer directly owned 120,058 shares in […]

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) insider Vincent Vultaggio sold 29,951 shares of Zentalis Pharmaceuticals stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the transaction, the insider directly owned 156,779 shares in the company, valued at […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) CFO Keith Goldan sold 3,410 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the sale, the chief financial officer directly owned 140,429 shares of […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) CEO Michael Metzger sold 17,159 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $360,853.77. Following the transaction, the chief executive officer directly owned 491,690 shares in […]

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) CEO Michael Metzger sold 7,412 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $20.62, for a total transaction of $152,835.44. Following the sale, the chief executive officer owned 508,849 shares of the company’s stock, […]

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CEO Christopher Peetz sold 9,108 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the sale, the chief executive officer directly owned 160,294 shares in […]

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) CFO Howard Horn sold 3,061 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the sale, the chief financial officer directly owned 88,935 […]